News Article

Cyrus Bio Co-Founder David Baker Featured in the New York Times

Inknowvation Site Notes

Anchored in work initiated by David Baker in his lab at University of Washington, Cyrus Biotechnology was founded in 2014 and only recently became SBIR-involved (NIH 2016). The firm is organized around an area of investigation that has fascinated scientists for two centuries but that it would seem Dr Baker and his colleagues have finally conquered – how to build human proteins. As this in-depth NYT article suggests, scientists at Cyrus (and elsewhere?) may “soon...be able to construct precise molecular tools for a vast range of tasks ……(with Dr Baker’s team already having) built proteins for purposes ranging from fighting flu viruses to breaking down gluten in food to detecting trace amounts of opioid drugs.”
Date: Jan 02, 2018
Source: Company Data ( click here to go to the source)

Featured firm in this article: Cyrus Biotechnology Inc of Seattle, WA



SEATTLE, WA January 02, 2018 -- Prof. David Baker, Cyrus Bio Scientific Co-Founder and Director of the Institute for Protein Design at the University of Washington, and the Rosetta software, have been prominently featured in the December 26th, 2017 New York Times article by Carl Zimmer, "Scientists are Designing Artisanal Proteins for Your Body."

The article illustrates how computationally building proteins from first principles are effectively targeting influenza, botulism, opioids, gluten intolerance, gene therapy and immuno-oncology.

Gary Nabel, Chief Scientific Officer at Sanofi, is quoted saying that "the new research may lead to the invention of molecules we can't yet imagine."

Cyrus Bench® is a Software-as-a-Service platform based on the Rosetta protein modeling toolkit for protein structure prediction, discovery, modeling, stabilization, engineering and design, making some of the methods developed at Prof. Baker's lab available to a wider audience of scientific users in Pharmaceutics, Chemicals, Consumer Products, Academia and Non-Profits.

Click here to access the article. A subscription to the New York Times may be required.